Podcasts about Cancer vaccine

In this episode of the Scope of Things, host Deborah Borfitz delivers the latest on an AI-powered trial screening tool that outperforms research staff, a strategy report on ways to boost cancer vaccine work, the continued absence of pregnant women in clinical trials, a program bringing studies directly to people in rural Utah, and efforts to integrate clinical trials into routine patient care in medically underserved areas of Oklahoma. Wes Michael, founder and president of Rare Patient Voice, also joins in to discuss how his company is connecting people undertaking research studies with participants eager to share their insights—and getting paid to do so. News Roundup  AI clinical trial screening tool Research letter in JAMA  Strategy report on cancer vaccines Commentary in Cambridge Prisms: Precision Medicine  Exclusion of pregnant women from trials Article in American Journal of Obstetrics and Gynecology Bringing cancer care and trials to Utah's rural residents Press release on Huntsman Cancer Institute website Integrating clinical research into primary care News on OU Health Sciences website Guest Wes Michael, president and founder of Rare Patient Voice The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

More with Mayo Clinic's Dr. Bill Morice as he gets into the medical community's renewed hope for cancer vaccines to become a reality. Also - the very concerning and ongoing issue of cyberattacks on hospitals and healthcare. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

More with Mayo Clinic's Dr. Bill Morice as he gets into the medical community's renewed hope for cancer vaccines to become a reality. Also - the very concerning and ongoing issue of cyberattacks on hospitals and healthcare. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Infosec Decoded Season 5 #11: Cancer VaccineWith Doug Spindler and sambowne@infosec.exchangeLinks: https://samsclass.info/news/news_020725.htmlRecorded Fri, Feb 7, 2025

A US judge temporarily blocks Trump's freeze on all federal grants and loans, Serbian Prime Minister Miloš Vučević resigns, Argentina moves to build a fence at the Bolivian border, the EU decides to ease sanctions on Syria, Israel continues its offensive in the West Bank, Trump announces four new executive orders to reshape the military, Microsoft reportedly considers buying TikTok, Several prosecutors who handled Trump's former criminal cases are dismissed, India and China agree to resume direct flights after a 5-year suspension, and the UK's GSK and Oxford reach a $62M deal to research cancer vaccines. Sources: www.verity.news

Physician & mRNA pioneer, Robert Malone, MD, joins Del to discuss tech giant Larry Ellison's recent promotion of employing mRNA vaccine technology to fight cancer. Get his expert view on his serious concerns about this technology that has already been proven to be dangerous and how Moderna has nearly gone bankrupt in the past after years of failed attempts of creating a vaccine for cancer. Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Dr. Anu Gaba, from Sanford Health, explains where the trials for a new breast cancer vaccine are at and what to expect. See omnystudio.com/listener for privacy information.

A lot has transpired since our last episode. We have a president again! And now Big Tech is telling us we can have a personalized AI-generated cancer vaccine within 48 hours based on the results of a blood test. Incredible! Is anyone else a bit skeptical of this nonsense?

Patrick Bet-David, Tom Ellsworth, Vincent Oshana, and Adam Sosnick cover Trump's clash with John Bolton, Larry Ellison's groundbreaking cancer vaccine, the Obama's rumored divorce, and Trump's war against woke culture. ----

With news about a possible Cancer Vaccine, Dan Mandis weighs in on this contraversial idea.See omnystudio.com/listener for privacy information.

Cancer is a disease that will affect 1 in 5 people in our lifetime, and it's estimated that around 20 million people worldwide will be diagnosed with some form of cancer in 2025.But how might a vaccine help in the treatment of cancer?Numerous trials began testing the viability of cancer vaccines in 2024, including one for Melanoma and another for Lung Cancer. With all the promise that these new cancer vaccine trials bring for cancer patients, we explore the different ways in which vaccines could work within the body, and how the time at which future vaccines are administered may vary according to the cancers they are targeting.This week on the Inquiry we're asking: Are we close to a cancer vaccine?Presenter: Tanya Beckett Producer: Matt Toulson Researcher: Katie Morgan Production Coordinator: Tim Fernley Editor: Tara McDermott Studio Director: Craig Boardman Contributors: Meredith McKean, director of Melanoma and Skin Cancer Research for Sarah Cannon Research Institute at Tennessee OncologySamra Turajlic, Chief Investigator of translational studies into melanoma and kidney cancer at the Francis Crick Institute and Professor at the Institute of Cancer Research Eduardo Vilar-Sanchez, professor in the department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer CenterPatrick Ott, Clinical Director at Melanoma Disease Center at the Dana-Farber Institute

Welcome to The Political Purple Breakdown, a feature of US RESIST NEWS, a nonprofit news service dedicated to providing truthful reporting in an age of disinformation. Join host Radell Lewis as we explore the intersection of U.S. domestic and international issues, offering insightful analysis on the stories shaping our world today. Learn more at www.usresistnews.org.

Today we see that Feds Banned Drones of the New Jersey Area Air Space. Pastor Stan also shares 8 Tell-Tale signs the U.S. Government is Lying about the “Mysterious Drones”. In other news, Russia says it’s developed a Cancer Vaccine and will launch it for free. 00:00 – Intro 06:53 – Feds Ban Drones 09:09 – Eight Signs 13:03 – Cancer Free Vaccine 15:58 – Quantum Chip 19:15 – QFS Destroys Banking System 24:28 – Our Sponsors

Today we see that Feds Banned Drones of the New Jersey Area Air Space. Pastor Stan also shares 8 Tell-Tale signs the U.S. Government is Lying about the “Mysterious Drones”. In other news, Russia says it’s developed a Cancer Vaccine and will launch it for free. 00:00 – Intro 06:53 – Feds Ban Drones 09:09 – Eight Signs 13:03 – Cancer Free Vaccine 15:58 – Quantum Chip 19:15 – QFS Destroys Banking System 24:28 – Our Sponsors

Welcome to The Club! What country are Americans moving to the most? Also, does Russia really have a cancer vaccine?

The Economist's health editor Natasha Loder wrote that advances in mRNA technology have spawned groundbreaking new cancer vaccine trials around the world, from melanoma to colorectal cancers.

Get your FREE copy of “Your A-Z Guide to Staying Cancer Free” here: https://bit.ly/azcancerfree New Research! New findings were released on the Triple Negative Breast Cancer Vaccine.   This is starting to sound promising.   Of course vaccines are quite controversial. But triple negative has such few treatment options so it's always nice to see more development.  More treatment options is always a good thing.  So if you are a triple negative breast cancer survivor or at high risk of developing breast cancer, this video is for you! So let me show you how it's done.   Join the Cancer Freedom Program Click HERE www.cancerfreedomprogram.com   #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery  #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane    ***PS - Whenever you're ready, here are the 2 best ways I can help you… 1) “Your A-Z Guide to Staying Cancer Free” **FREE** Click HERE https://bit.ly/azcancerfree   2) Join the Cancer Freedom Program Click HERE www.cancerfreedomprogram.com   ***Let's Connect: Website: www.cancerfreedomprogram.com Instagram: https://www.instagram.com/dramymorris/ YouTube: https://www.youtube.com/channel/UCUt9... Facebook: https://www.facebook.com/dramycancer/

Sarah Blagden, pioneer in experimental oncology, returns to the podcast to discuss cancer prediction and prevention, and the future of cancer vaccines. Timestamps: (00:00)- Introduction (00:35)- The mission of RNA Guardian Ltd (02:02)- mTOR in cancer biology (06:24)- Raising awareness of ovarian cancer (08:32)- A new era of cancer prediction and prevention (11:38)- The future of cancer vaccines (15:58)- Advice to medical students: academia versus medicine (19:42)- Sarah's three wishes for healthcare

It's nearly thirty years since Kelly Macdonald made her acting debut as the sharp-witted 15 year old schoolgirl Diane in the classic film Trainspotting. Since then, the award winning actress has starred in critically acclaimed films like No Country for Old Men, Gosford Park, as well as Harry Potter franchise, and voiced the fearless Princess Merida in Pixar's Brave. Now, she's taking on a new role in the vampire comedy thriller, The Radleys.Scientists at the University of Oxford are creating OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The hope is that the jab could be given to women preventatively on the NHS with the aim of eliminating the disease. We talk to Professor Ahmed Ahmed from the university of Oxford, who is leading the research into the jab, and Cary Wakefield CEO of Ovarian Cancer Action, to find out when exactly we might see this becoming available.Hundreds of women have recently been protesting in Turkish cities after the killing of two young women in Istanbul – followed by protests every day for a week across the country, notably on university campuses. Recently the "We Will Stop Femicide Platform" reported that in Turkey, 34 women were murdered by men and 20 more died under suspicious circumstances in September alone. We hear from Elif Shafak - award-winning British-Turkish novelist and storyteller, and Times Turkey Correspondent Hannah Lucinda Smith.Presenter: Nuala McGovern Producer: Laura Northedge

Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine at the University of Oxford, is leading the research into the first ovarian cancer vaccine. The hope is that the jab could one day be given to women preventatively on the NHS with the aim of eliminating the disease.Tech & Science Daily speak to the creator of a device helping people with Parkinson's to walk.Martijn van der Ent, Medical Director and co-founder of Cue2Walk International, explains how they created the sensor worn on the leg that detects movements and automatically triggers a rhythmic signal.Also in this episode:Google introduces new way to search by filming videoTikTok influencer 'Mr Prada' arrested for second degree murderNearly £22 billion pledged for UK carbon capture projectsHas Nessie been found? Loch Ness skipper shares pictures of monster-like shape caught on sonar Hosted on Acast. See acast.com/privacy for more information.

A closer look at unexpected trends in dating as more young people are ditching the dating apps to find love in person. Also, inside the push to create a safe and effective vaccine for breast cancer. Plus, in honor of Hispanic Heritage Month, pastry chef Paola Velez shares a delicious coquito cheesecake recipe.

Today, Saranne welcomes Kristen Dahlgren, the former Today Show correspondent and now the dynamic founder and CEO of the Cancer Vaccine Coalition. Together, they explore the practical aspects and challenges of traveling with cancer. Kristen shares her insights on maintaining health and well-being while traversing the globe, touching everything from packing strategies to navigating airport security with medical needs. Their conversation is filled with humor and heartfelt advice, aiming to empower cancer survivors and patients to embrace their wanderlust safely. Kristen Dahlgren has built a remarkable career as an NBC correspondent, covering significant global events like the Olympics and major natural disasters. Following her cancer diagnosis, Kristen has transitioned into a passionate advocate for cancer vaccines, leading the Cancer Vaccine Coalition. Her journey through cancer treatment and survivorship fuels her dedication to advancing cancer research and supporting patients worldwide. "If you have to do it, you may as well make it fun." – Kristen Dahlgren Today on Beating Cancer Daily: ·     Packing extra prescriptions and being prepared for medication theft can be vital when traveling.·     Wearing lymphedema sleeves with fun designs can add a bit of joy to necessary medical equipment.·     Keeping vaccines up to date is crucial, especially when traveling internationally.·     Bringing a paper or digital medical file ensures proper care in emergencies.·     Regularly moving during flights helps manage swelling and improve circulation.·     Advocating for special accommodations with airlines can significantly ease the travel experience.·     Eating healthy on the road requires planning, like packing snacks or shopping for fresh foods upon arrival.·     Trial local trips can build confidence and experience managing travel while undergoing treatment. Resources Mentioned: Cancer Vaccine Coalition: https://cancervaccinecoalition.org/ ComedyCures Foundation: https://www.comedycures.org The #1 Rated Cancer Survivor Podcast by FeedSpot and Ranked the Top 5 Best Cancer Podcast by CancerCare News, Beating Cancer Daily is listened to in more than 91 countries on 6 continents and has over 300 original daily episodes hosted by stage IV survivor Saranne Rothberg!   Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org? By becoming a supporter of ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide. Choose your level of support: • Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annually Donate Herehttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJT

In this episode of the SHE MD podcast, Kristen Dahlgren and Dr. Kiran Dhillon join us to discuss groundbreaking vaccines being developed to prevent and treat breast cancer. Did you know that one in eight women will be diagnosed with breast cancer in their lifetime? The first vaccines being developed are targeting the most aggressive forms of the disease, offering hope to those who need it now. Kristen and Dr. Dhillon share their involvement with the Cancer Vaccine Coalition and highlight the progress in targeting aggressive cancers such as ductal, lobular, and inflammatory breast cancers. They explain the challenges of funding these life-saving vaccines, the importance of early detection, and the role of personalized medicine. Tune in to learn about current clinical trials, how vaccines stop cancer recurrence, and how listeners can support this vital research. For more resources, visit our website: SheMDpodcast.comFollow us across social media: @SheMDpodcastSponsors: Knowing your family's history of cancer is the first step to understanding your own cancer risk and may qualify you for the MyRisk Hereditary Cancer Test with RiskScore hereditary cancer test. It's easy, accurate and covered by most insurers. Learn more at GetMyRisk.com, https://myriad.ws/getmyrisk If you want to take ownership of your health, it starts with AG1. Try AG1 and get a FREE 1-year supply of Vitamin D3K2 AND 5 free AG1 Travel Packs with your first purchase at drinkAG1.com/shemd.Get 10% off your first order sitewide with code SHEMD at OSEAMalibu.comRedefine learning with play! Get 50% off your first month on ANY crate line at KIWICO.com, promo code SHEMD. IN THIS EPISODE:[00:00] Kristen and Dr. Dhillon explain how they got involved in the Cancer Vaccine Coalition.[05:06] The different types of cancers and vaccines developed to target them; examples are ductal, lobular and inflammatory[09:15] There are vaccines available; however, Kristen says there isn't the funding needed and discussion of a study that started ten years ago and timelines for making the vaccines available to the public[18:38] Kristen discusses barriers to working on vaccines, the composition of the Cancer Vaccine Coalition and personalized vaccines, and Dr. A tells about her journey with breast cancer[25:28] Why younger women and men are getting cancer, how does the inflammation factor weigh in[38:35] Vaccines and trials for BRCA-positive patients[47:24] Dr. Dhillon explains how vaccines work, the current active studies and getting scientists together from all over the world to collaborate[53:31] Results of the breast cancer study, expediting the studies and the number of clinical trials going on now and how much money it would take to completely fund those trialsKEY TAKEAWAYS: Schedule Regular Screenings: Encourage regular screenings for those you know. Breast cancer can affect anyone, regardless of family history.Support Cancer Vaccine Research: Donate to the Cancer Vaccine Coalition to help fund the development of life-saving breast cancer vaccines. The coalition does groundbreaking work in targeting aggressive breast cancers.Learn About Clinical Trials: If you or someone you know has breast cancer, explore current vaccine trials, especially if BRCA-positive. Kristen and Dr. Kiran discuss how listeners can get involved in these studies and help advance the development of vaccines.Stay Informed: Stay up to date on advancements in vaccines tailored to individual cancer profiles. This emerging field holds promise for treating cancers more effectively, and understanding your specific risks can lead to better treatment outcomes.Advocate for Increased Funding: Spread awareness about the need for more funding to make breast cancer vaccines widely available. Talk to your networks, share information from the episode, and encourage others to contribute to this critical cause.RESOURCES:Today Show - Kristen DahlgrenCancer Vaccine Coalition DONATE - WebsiteClinical Trials - GovCancer Vaccine Institute Trials- WebsiteNewsletter Sign UpCONNECT WITH SHE MD: Mary Alice Haney - InstagramDr. Thaïs Aliabadi - InstagramSheMD Podcast - InstagramSHEMD - YouTubeSHEMD - PodcastQUOTES:“We're trying to find these proteins pushing these cancer cells to grow and metastasize, and then lurk around and come back years later and get the immune system to see those as dangerous, just like you might see the COVID-19 virus or something like that. Then we go after those.” -Dr. Kiran Dhillon“It's incredible to me that I, a journalist, with not oodles of money like the federal government, must try and put together the funding to support this incredible research….we certainly have hospitals and academics that are willing to work together along with pharmaceutical companies and get these into widespread trials quickly because we're losing thousands of women and men every year. So we can say well, we will have these vaccines in 20 to 30 years, or we can create a movement where we say this is not acceptable and we fund the research, and we get this moving to save lives.” -Kristen Dahlgren See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, Saranne welcomes Kristen Dahlgren, a dedicated cancer vaccine advocate, to share her unique journey of finding solace and strength through writing amidst her battle with Stage IV cancer. Kristen opens up about the importance of capturing reflections during a cancer experience and how these moments, intertwined with humor and creativity, helped not only her but also her daughter, CeCe, who is actively involved in advocacy through the Cancer Vaccine Coalition. Together, they delve into ways to involve children in this journey, making them active participants in the fight against cancer. Kristen Dahlgren, a seasoned journalist and former NBC correspondent, has bravely faced the challenges of Stage IV cancer. Known for raising awareness about cancer vaccines, Kristen is now the CEO and founder of the Cancer Vaccine Coalition. Her candid and heartfelt approach to her cancer journey and her professional background make her a powerful and inspiring voice in the cancer community. "We must find ways to laugh even in the darkest of times, as humor can light the path through our toughest battles." – Kristen Dahlgren Today on Beating Cancer Daily: ·     Sharing reflections and humor during the cancer journey can be healing. Involving children in advocacy efforts helps them process and cope with a parent's cancer.·     Creative activities and humor, like drawing on bald heads, can relieve emotions.·     Honest and age-appropriate communication with children is crucial in reducing their fear of cancer.·     Reassure children that cancer is neither contagious nor their fault.·     Accessibility and fun in using wigs, caps, and scarves can positively impact morale.·     Creating a community through sharing stories and poems offers immense support.·     Embrace humor and positivity even during challenging treatments, as it helps navigate the journey effectively. Guest Contact Information: Kristen Dahlgren:  Cancer Vaccine Coalition https://cancervaccinecoalition.org/ Resources Mentioned: ComedyCures Foundation https://www.comedycures.org  Healing Headbands https://www.healingheadbands.com/ The #1 Rated Cancer Survivor Podcast by FeedSpot and Ranked the Top 5 Best Cancer Podcast by CancerCare News, Beating Cancer Daily is listened to in more than 91 countries on 6 continents and has over 300 original daily episodes hosted by stage IV survivor Saranne Rothberg!   Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org? By becoming a supporter of ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide. Choose your level of support: • Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annuallyDonate Herehttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJT

Recently, doctors announced some extremely encouraging news about a jab for people with advanced forms of several types of malignancy, including melanoma, lung cancer and other solid organ tumours. The vaccine is called mRNA-4359 and has been developed by the pharmaceutical company Moderna, of Covid vaccine fame. The trials have been conducted here in the UK, and we'll hear from the man running the study. Also, the success of the HPV vaccine in preventing cervical cancer, and how a Lynch syndrome vaccine could prevent a variety of malginancies... Like this podcast? Please help us by supporting the Naked Scientists

Today on Beating Cancer Daily, Saranne welcomes Kristen Dahlgren, a former NBC correspondent and Today's Show medical reporter renowned for her advocacy of cancer vaccines following her breast cancer diagnosis. The episode sees an insightful discussion on the deeply personal choice of revealing a cancer diagnosis publicly, the responsibilities tied to being a medical advocate, and the balance between maintaining control over one's narrative and the unintended repercussions of newfound fame. Kristen Dahlgren is a distinguished journalist who transformed her personal battle with breast cancer into a global mission for cancer vaccine advocacy. Finding her own cancer five years ago, a journey that began with a breast dent and culminated in a Stage II diagnosis, she has utilized her platform to raise awareness and promote advancements in cancer vaccines. Kristen's work is deeply rooted in her commitment to making cutting-edge treatment accessible, underscored by her position in the Cancer Vaccine Coalition. "The importance of awareness about breast cancer symptoms that are not typical lumps cannot be overstated." – Kristen Dahlgren Today on Beating Cancer Daily: ·     Breast cancer symptoms can manifest as more than just lumps; awareness of lesser-known signs is crucial.·     Maintaining personal control over one's cancer story can help navigate the challenges of public exposure.·     Involvement in cancer advocacy often requires setting clear boundaries to prevent burnout.·     Honesty in sharing personal experiences, such as wearing a wig during chemotherapy, can provide comfort to others in similar situations.·     Engaging children in advocacy work can shape their perspectives and ambitions positively.·     Taking breaks from advocacy and incorporating humor can alleviate the intense emotional toll of cancer-related work.·     The Cancer Vaccine Coalition's "Give us a shot" campaign provides a platform for sharing personal cancer journeys and raising awareness.·     Working collaboratively with top cancer researchers can expedite the development and accessibility of life-saving vaccines. Resources Mentioned:ComedyCures Foundation: https://www.comedycures.org31-Day Tumor Humor Challenge: https://www.saranne.com/Cancer Vaccine Coalition: https://cancervaccinecoalition.org/ Guest Contact Information:Kristen Dahlgren: ComedyCures.org https://www.comedycures.orgCancer Vaccine Coalition: https://cancervaccinecoalition.org/ The #1 Rated Cancer Survivor Podcast by FeedSpot and Ranked the Top 5 Best Cancer Podcast by CancerCare News, Beating Cancer Daily is listened to in more than 91 countries on 6 continents and has over 300 original daily episodes hosted by stage IV survivor Saranne Rothberg!   Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org?By becoming a supporter of ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide. Choose your level of support: • Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annually Donate Herehttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJT

Scientists University of Southampton and Monash University in Australia are working on what's described as a “breakthrough” cancer vaccine after discovering how the body's immune system targets diseased cells. UN Secretary-General's rising sea levels warning. ‘Son of Concorde' supersonic jet's happy landings milestone.Also in this episode:CoD Black Ops 6: release date and beta updateSpaceX's Falcon 9 grounded after landing failVirtual research centre studies lab-grown meatHit weekend snooze button ‘to lower heart disease risk' Hosted on Acast. See acast.com/privacy for more information.

Trials of a cancer 'vaccine' have begun and presenter James meets Steve, one of the first patients to trial the new treatment, Steve remembers his shock at being diagnosed with colorectal cancer in his 40s and tells the story of how he became involved in this pioneering research into tackling cancer.The vaccine is based on the same mRNA technology as the Pfizer-BioNTech COVID-19 vaccine and James heads to the University of Cambridge to find out how the early work into cancer vaccines became the foundation for the rapid rollout of the covid vaccine. In the lab, molecular biologist Dr Anne Willis and immunologist Dr James Thaventhiran explain how the vaccine is personalised to target the unique make-up of an individual patients' cancer cells, and how if the trials are successful they could open the door to mRNA treatments being used to treat a wide range of diseases.Also, Imperial College London cyber security researcher Dr Saira Ghafur joins James in the studio to explain why healthcare is a growing target for cyber attackers and how we can prepare for the next one because, as Saira says, it really is a case of "when" not "if".Presented by James Gallagher Produced by Tom Bonnett with Hannah Robins Assistant Producer: Katie Tomsett Editor: Holly Squire

We'd love to hear from you! Send us a text message.In this episode of "Discover Daily," we delve into the arrest of Telegram founder Pavel Durov in France, exploring the allegations of insufficient content moderation and the potential implications for free speech platforms worldwide. We examine the charges against Durov and Telegram, the alleged violations of the Digital Services Act, and the company's response to these accusations. We then shift our focus to Meta's decision to cancel its high-end mixed reality headset project, codenamed "La Jolla," which was intended to compete with Apple's Vision Pro. We discuss the reasons behind this cancellation, including high production costs and the lukewarm market reception of similar devices, while exploring Meta's ongoing commitment to developing more affordable mixed reality devices.Finally, we explore the groundbreaking lung cancer vaccine trial that has begun across seven countries. We examine how BioNTech's mRNA-based vaccine BNT116 works, its potential to revolutionize cancer treatment, and the preliminary results from early trials. We discuss the vaccine's targeted approach, its differences from traditional chemotherapy, and the implications for the future of cancer immunotherapy.From Perplexity's Discover Feed:https://www.perplexity.ai/page/telegram-founder-arrested-in-f-LfP78tciSl.8w9ezhGfjCAhttps://www.perplexity.ai/page/meta-cancels-vision-pro-compet-0YdufFfWSuOpvewDU4W1.Ahttps://www.perplexity.ai/page/first-lung-cancer-vaccine-tria-zGag7w53Qq.FiPhAm2.wCwPerplexity is the fastest and most powerful way to search the web. Perplexity crawls the web and curates the most relevant and up-to-date sources (from academic papers to Reddit threads) to create the perfect response to any question or topic you're interested in. Take the world's knowledge with you anywhere. Available on iOS and Android Join our growing Discord community for the latest updates and exclusive content. Follow us on: Instagram Threads X (Twitter) YouTube Linkedin

A new lung cancer vaccine has been tested on a UK patient for the first time.BNT116 is designed to treat non-small cell lung cancer - also known as NSCLC - the most common form of the disease.Professor Siow Ming Lee, consultant medical oncologist at University College London Hospitals NHS Foundation Trust, and chief investigator for the trial in the UK, tells Tech & Science Daily how it works, and why this could be game changing for lung cancer patients around the globe. If you're in London docklands this weekend, we'll tell you why you may see a 2.5-ton block of ice suspended from a crane. Joshua Thomson from Australian physical theatre company Legs On The Wall, discusses their new performance THAW by and why they hope to highlight the impact of climate change.Also in this episode:SpaceX reveals date for first ever commercial spacewalkIceland volcano erupts again with huge plumes of lava visible from ReykjavikTerrifying dinosaur discovered with 'distinctive eyebrows'Follow us on X or on Threads. Hosted on Acast. See acast.com/privacy for more information.

Researchers say the Wet Bulb Globe Temperature is a better indicator of heat stress. Also, cancer is the leading cause of death in dogs. A new vaccine has increased survival rates in clinical trials, offering hope for dogs and humans.Yes, It's Hot. But How Hot?Much of the country has been enduring a heat wave this week, with millions sweating from Maine to the Midwest. But describing exactly how hot it is—and when temperatures become hazardous—can be challenging. Beyond the basic temperature, there's the heat index, invented in 1978, which incorporates humidity measurements and is supposed to give a better indication of how a person might feel outside. Some health researchers are calling for more attention to a different type of temperature measurement known as the wet bulb globe temperature. It tracks temperature, humidity, and sunlight, and improves upon the heat index standard.Umair Irfan, senior correspondent at Vox, joins SciFri's Kathleen Davis to talk about measuring temperatures and protecting yourself from extreme heat. Plus, they discuss other stories from the week in science, including advances in tornado prediction, a delay in a return flight from the International Space Station, and a newly-described horned dinosaur that once roamed the US.A Canine Cancer Vaccine Shows Promising ResultsDogs are by far the most popular pet in the United States: 62 million households have at least one. They are humans' best friends, after all. Sadly, cancer is the leading cause of death in domestic dogs. And when a pet gets sick, it can be devastating for the entire family.Lucky for dogs (and their people), there may soon be a breakthrough in treating canine cancer: a vaccine that can slow and even stop the spread of tumors. Clinical trial results are quite promising so far, increasing 12-month survival rates in dogs with some cancers from 35% to 60%. The research team also reports that in many dogs the vaccine shrinks tumors.Joining guest host Kathleen Davis to talk about this novel therapy is Dr. Mark Mamula, professor of medicine at the Yale School of Medicine in New Haven, Connecticut. Mamula discusses this important breakthrough, and possible future applications for human cancer therapies.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Hour 3 - Marty takes more callers about Pittsburgh Public Works and discusses the new vaccine for breast cancer.

Dr. Natalie Gentile, physician and founder of Direct Care physicians of Pittsburgh, calls in to talk with Larry about the great potential the breast cancer vaccine has.

Send us a Text Message.Discover the groundbreaking advancements in veterinary oncology with Ashley Kalinauskas, CEO of Torigen. Learn how personalized cancer vaccines are revolutionizing pet cancer treatment by using a pet's own tumor cells. This episode of Vetsplanation delves into the science behind these innovative vaccines and their impact on thousands of pets. Don't miss this insightful discussion on the future of veterinary medicine.In this episode you will learn:How personalized cancer vaccines for pets are developedThe science behind using a pet's own tumor cells for treatmentTypes of cancers targeted by Torigen's vaccinesPractical steps in creating and administering the vaccinesBenefits and potential side effects of the treatmentCombining immunotherapy with chemotherapy and radiationInsights into the future of veterinary oncologyTorigen's role in advancing cancer treatments for petsReal-life examples and success stories of treated petsHow veterinarians and pet owners can access and utilize these treatmentsResourcesTorigen's WebsiteSupport the Show.Connect with me here: https://www.vetsplanationpodcast.com/ https://www.facebook.com/vetsplanation/ https://www.twitter.com/vetsplanations/ https://www.instagram.com/vetsplanation/ https://www.tiktok.com/@vetsplanation/ https://youtube.com/@Vetsplanationpodcast https://www.youtube.com/playlist?list=PLVbvK_wcgytuVECLYsfmc2qV3rCQ9enJK Voluntary donations and Vetsplanation subscription: https://www.paypal.com/donate/?hosted_button_id=DNZL7TUE28SYE https://www.buzzsprout.com/1961906/subscribe

Dr. Michael Blankenship, from ima Healthcare, joins Amy & JJ to talk about a new skin cancer vaccine in trial right now. There's a new vaccine that's created a 96 percent survival rate for people with the condition. The treatment is actually a combo of a vaccine and an immunotherapy drug. About 75 percent of the patients in the trial had no recurrence of the disease. Experts say it could be one of the "single biggest developments" to fight melanoma. See omnystudio.com/listener for privacy information.

The news to know for Tuesday, June 4, 2024! We'll tell you about President Biden's action that might close the southern border immediately. Also, there was another dramatic hearing on Capitol Hill, this time involving Dr. Anthony Fauci, and a heatwave is set to impact millions of Americans this week. Plus, there is new promising data about a melanoma vaccine; a new policy allows x-rated content on X, and gymnast Simone Biles broke another record. Those stories and more news to know in about 10 minutes! See sources: https://www.theNewsWorthy.com/shownotes Sign-up for our bonus weekly email: https://www.theNewsWorthy.com/email Get The NewsWorthy merch here: https://www.theNewsWorthy.com/merch Become an INSIDER and get ad-free episodes: https://www.theNewsWorthy.com/insider Episode Sponsors: Get a special deal with Hiya for their best selling children's vitamin: receive 50% off your first order at hiyahealth.com/NEWSWORTHY Get 20% OFF Honeylove by going to honeylove.com/newsworthy #honeylovepod To advertise on our podcast, please reach out to libsynads@libsyn.com    

Dr. Irshad M Essack, a dermatologist, joins John maytham on the Afternoon Drive show to delve deeper into how this vaccine works, its impact on melanoma patients, and the broader implications for cancer treatment.See omnystudio.com/listener for privacy information.

Visit NascentMC.com for medical writing assistance. Visit learnAMAstyle.com for information on AI in Medical Writing and Editing - **mRNA Anti-EBV Cancer Vaccine**: The novel mRNA therapeutic cancer vaccine WGc-043 has been approved for clinical trials by the FDA, targeting Epstein-Barr virus (EBV) related cancers such as nasopharyngeal carcinoma and natural killer T-cell lymphoma. It stimulates the immune system to respond against EBV and associated malignancies, showing superior efficacy and safety in preliminary trials. A phase 1 clinical trial is currently focusing on patients who have failed second-line therapies, aiming to determine the optimal dose and evaluate safety and efficacy metrics. - **BTX-9341 for Breast Cancer**: The FDA has approved the investigational new drug application for BTX-9341, a novel cyclin-dependent kinase (CDK) 4/6 bifunctional degrader, intended for hormone receptor-positive, HER2-negative breast cancer resistant to existing CDK4/6 inhibitors. This drug targets and degrades CDK4/6 proteins, crucial for cancer cell cycle regulation, aiming to overcome resistance to current treatments. A phase 1 trial will assess its safety, biological activity, and efficacy both as monotherapy and combined with fulvestrant. - **Nivolumab Hyaluronidase Formulation**: The FDA has accepted a Biologics License Application for a subcutaneous formulation of nivolumab co-formulated with recombinant human hyaluronidase, enhancing convenience by reducing administration time compared to the intravenous version. This application includes all previously approved solid tumor indications for nivolumab, with a PDUFA date set for February 28, 2025. The subcutaneous version aims to provide faster and easier administration, supported by data from the Phase 3 CheckMate-67T study. - **ColoSense Colorectal Cancer Screening Test**: The FDA has approved ColoSense, a noninvasive colorectal cancer screening test using multi-target stool RNA for adults aged 45 and older at average risk. ColoSense, distinct from traditional FOBT tests, uses RNA biomarkers to detect CRC with high sensitivity and has shown promising results in clinical trials, detecting 93% of CRC cases and 45% of advanced adenomas in average-risk individuals. This new test offers a significant improvement in sensitivity and specificity over existing methods. For the complete shownotes visit nascentmc.com/podcast

Beating Cancer Daily is the #1 ranked Cancer Survivor Podcast in 2024, helping listeners daily in 73 countries with over 250+ episodes. Today is super fun because Saranne invites you to her unique “Pajama Party” guest episode! Join Saranne and award-winning NBC correspondent, cancer survivor, and cancer advocate Kristen Dahlgren in their hotel room at the American Association of Cancer Research (AACR) Conference. And yes, they really are talking to you in their pajamas as they spontaneously share Saranne's podcast microphone (on Saranne's bed) to let you in behind the scenes in San Diego at this massive international cancer conference with 22,000 cancer researchers and cancer experts. (See their Beating Cancer Daily pajama podcast episode photo @ComedyCures.)Learn why Kristen, a medical reporter for NBC, The Today Show, and The Nightly News for more than two decades, traded in her journalism credentials live on the air, just weeks ago, for a role on the frontlines of cancer advocacy.Laugh with these two cancer survivors as they share why “This is the most hopeful time in cancer research.”Dive deeper into why Kristen and Saranne are collaborating with the top scientists to accelerate cancer vaccine discoveries. You will uncover why you should care and then hopefully join their research movement. You can even win your very own “Cancer Research Pajama Party”!This is more than an episode; it's an invitation to be part of history with indomitable souls who are turning the fight against cancer into a mission filled with joy, humor, science, and unwavering dedication to others.Upon launching her “Pink Eraser Project,” Kristen was introduced to stage IV survivor Saranne, who has been cancer-free for decades and serving as a global patient advocate. In 1999, Saranne launched The ComedyCures Foundation from her chemo chair with a "Chemo Comedy Party." Saranne has dedicated her life to helping others find strength, courage, empowerment, and laughter in their fight against cancer. As a healthcare thought leader, cancer researcher, speaker, patient advocate, and happiness expert, Saranne's work has garnered recognition and support from prestigious organizations like the NIH/NCI, the United Nations, the World Health Organization, AACR, ACS, Komen, numerous universities, hospitals, and cancer organizations. Saranne's transformative strategies, research findings, fun, practical tips, and comic insights can be found throughout the Beating Cancer Daily podcast, helping listeners to navigate their treatment and survivorship with humor and resilience.Are you wondering How You Can Support Beating Cancer Daily and ComedyCures?Supporting ComedyCures will help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide.Choose your level of support:• Supporter: $60 (or $5 per month)• Friend: $180 (or $15 per month)• Champion: $600 (or $50 per month)• VIP: $5,000 annuallyDonate HereShare the Laughter with Beating Cancer Daily Podcast.Do you love the podcast, or do you have a suggestion? Go to ComedyCures.org and record a message or write a note to Saranne.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we'll discuss another cancer vaccine clinical trial that got the green light from the Food and Drug Administration.  FDA Approved Besponsa for Children With Acute Lymphoblastic Leukemia The first FDA approval of last week was one in the pediatric cancer space. The agency approved Besponsa for children who are at least 1 year old and have relapsed or refractory CD22-positive precursor acute lymphoblastic leukemia., also known as ALL.  The approval is coming after findings from a single-arm study involving 53 children. Of which, 22 — that's 42% — achieved a complete response from the therapy, with the median duration of complete response being 8.2 months. Additionally, the majority of patients who achieved a complete response also had minimal residual disease negativity, which indicates that there were 5% or less blasts found in the bone marrow and no cancer cells detected in the blood.  Having a new treatment option for children with ALL is particularly exciting, as ALL is one of the most common pediatric cancers, according to the American Cancer Society.  FDA Approves Opdivo Plus Chemo for Unresectable or Metastatic Bladder Cancer Last week, the FDA also approved an immunotherapy/chemotherapy regimen for certain patients with bladder cancer. Specifically, the agency OKed Opdivo plus cisplatin and gemcitabine for the frontline treatment of adults with unresectable or metastatic urothelial carcinoma.  This approval was backed by findings from the CheckMate-901 trial, which showed that the Opdivo-chemotherapy regimen improved overall survival (which is the time patients live before death of any cause) and progression-free survival (which is the time patients live without their disease worsening) compared to those who did not receive Opdivo. The median overall survival was 21.7 months for those who received Opdivo compared to 18.9 months for those who did not, while progression-free survival was 7.9 and 7.6 months, respectively.  FDA Approves Brukinsa, Gazyva Combo for Relapsed, Refractory Follicular Lymphoma Last week, the Food and Drug Administration also approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma after findings from the ROSEWOOD trial showed that not only did more patients respond to the two-drug treatment compared to Gazyva alone, but also at a median follow-up of 19 months, more patients were still responding compared to the Gazvya arm as well.  Rhabdomyosarcoma Survivors May Have Poor Psychological Outcomes A study published in the journal, Cancer, found that survivors of rhabdomyosarcoma — which is a rare cancer affecting soft tissues — may face increased risk of psychological challenges, especially if they were exposed to previous radiation therapy or have a history of smoking. Researchers examined neurocognitive impairment, emotional distress and health-related quality of life in survivors compared to their siblings. Results showed higher rates of issues like memory impairment and emotional distress among survivors, with smoking linked to poorer outcomes. The CURE® team spoke with study author, Ellen van der Plas on the findings. Here is what she had to say.  Ovarian Cancer Vaccine Trial Gets FDA Clearance to Proceed The FDA has given the green light for a clinical trial of a vaccine designed to treat advanced ovarian cancer. Known as Innocell, this personalized therapy utilizes cells from the patient's own tumor which is inactivated via riboflavin and UV light. The drug is being manufactured at City of Hope in Los Angeles, and the trial aims to assess the vaccine's safety and effectiveness in stimulating immune response. This is one of the many cancer vaccines being explored and developed in the oncology space. Check back on prior CURE® coverage for updates on vaccines to treat breast, lung, skin and other cancers.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

Being stuck in a role Making it out of being stuck Is the UFC making Sean Strickland act crazy?Russia has a cancer vaccine?Follow our IG offtopicpodcast34. Message us offtopicpodcast34@gmail.comFeel free to DM us and make friends!

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tumor testing, and physical activity for pain reduction in cancer survivors.  FDA Approves Onivyde as First-Line Treatment of Metastatic Pancreatic Cancer On Tuesday, the Food and Drug Administration approved Onivyde plus oxaliplatin, fluorouracil and leucovorin — a regimen referred to as NALIRIFOX — for the frontline treatment of patients with metastatic adenocarcinoma. The approval was based on findings from the NAPOLI 3 trial, which showed that the drug combination improved overall survival (which is the time after treatment patients live before death of any cause) and progression-free survival (time they live before their disease worsens) compared to a combination of gemcitabine plus nab-paclitaxel.  While this approval provides a new, promising treatment for this patient population, Dr. Anthony Shields of the Karmanos Cancer Center in Detroit mentioned that the Onivyde-containing regimen is not a cure.  “In our patients with advanced disease, this is not a curative therapy at this point,” Shields said in an interview with CURE®. “It clearly improves survival. It's still got its share of toxicities, though. … We need better drugs, despite the improvements. If patients get this regimen is the first line, inevitably if they're doing OK we will give gemcitabine/nab-paclitaxel (combination) as the second-line regimen. But we really don't have a third line regimen.” Cancer Vaccine Could Go ‘Above and Beyond Standard of Care' For Patients The oncology community is on the cusp of a sea change regarding cancer vaccines, as one expert told us. “Current vaccines have a dismal record, and minimal evidence of efficacy,” said Dr. Jeffrey S. Weber, deputy director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine, via email. Weber was among the researchers on recent KEYNOTE-942 study investigating mRNA vaccine mRNA-4157 (V940) and Keytruda versus standalone Keytruda for the treatment of patients with advanced-stage melanoma.With a median follow-up of 23 and 24 months, the recurrence or death rates were 22% and 40% and the 18-month recurrence-free survival rates were 79% and 62%, respectively. The Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the combination for the post-surgical treatment of patients with high-risk melanoma in 2023 based on the results of KEYNOTE-942. “This mRNA vaccine would be the first approved cancer vaccine with clear cut evidence of efficacy in a well-done phase 3 trial [which was recently initiated],” Weber said of mRNA-4157. Pharmaceutical companies Moderna and Merck have initiated V940-001, a phase 3 study evaluating mRNA-4157 and Keytruda as postsurgical treatment for stage 2B to 4 melanoma, announcing in June of 2023 that global patient recruitment had begun following primary analysis of the findings of KEYNOTE-942. Tumor Testing, ctDNA Finds More Patients Eligible for Personalized Drugs Circulating tumor DNA and tumor tissue-based testing can both help identify cancer characteristics that may point a patient toward a more targeted treatment regimen. Oftentimes, patients undergo only one of these two tests, but recent research showed that undergoing both of these tests may improve patients' chance of identifying targetable mutations.  Now, some patient populations — such as those with non-small cell lung cancer — may already be undergoing both tests in accordance with NCCN guidelines. The findings support that other groups in particular, such as those with breast cancer, may benefit from the dual testing modality.  In an interview with CURE, one of the study authors noted that the two tests can be “highly complementary,” and patients should talk to their health care teams about which test to undergo.  Physical Activity May Help Reduce Pain in Cancer Survivors Increased physical activity may be able to lessen pain in cancer survivors, according to one study.  Specifically, the researchers wrote, “Meeting or exceeding physical activity guidelines was associated with less pain intensity compared to being physically inactive. People who remained active longer term, were previously physically active or became active also reported less pain than those who remained inactive.”  These benefits were also seen in patients who were previously active but then became inactive — highlighting the possibility that the when it comes to pain reduction, the benefits of being active can stretch long-term. But interestingly, the was no association between  physical activity and painkiller use.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5%! GET ORGANIC COFFEE, MANUKA HONEY AND MUSHROOM TINCTURES HERE: https://madtravnutrition.com/ Use Code "Josh" and save 10%! Support the work of Jaymie Icke & Ickonic! HELP THE WAM LEGAL DEFENSE FUND HERE: https://gogetfunding.com/wam-legal-defense/ BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Josh Sigurdson reports on the new fake cancer vaccine announced by Russian President Vladimir Putin on television. He claimed that Russian scientists are close to completing a cancer vaccine that would cure cancer. Not only is this absurd, but there are already cures available in nature that have been suppressed by pharma for decades. Nonetheless, while the Mainstream Media attacks Putin and supports Zelensky, the mainstream alternative media are creating a "new narrative" that's convenient for the establishment as it distracts from the real truth and misdirects people towards blind allegiance to a fake alternative. The mainstream alternative media, a term popularized by David Icke, is now promoting a cancer vaccine because Putin announced it. Putin, the same guy who locked down, had vaccine mandates, is creating a CBDC and bows to the Chinese government. It's called "controlled opposition" and yet people are so easy to fall into it today due to the constant hyperbole and disingenuous claims by the media. The puzzle pieces are being fit together perfectly for the Great Reset. It goes without saying... DO NOT take the "cancer vaccine." Taking a vaccine in general is stupid. It's another level of stupid to take a cancer vaccine. Many countries have been working on so-called "cancer vaccines" for the past decade, most of which are mRNA based. Meanwhile, so many ignore apricot seeds, chlorine dioxide, CBD-A, Vitamin C, etc. Stay tuned for more from WAM! ORDER QUALITY MEAT TO YOUR DOOR HERE: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 Save 20% and get $15 off your FIRST order! Support your local farms and stay healthy! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ GET AN EXTENDED FREE TRIAL FOR ICKONIC WHEN YOU SIGN UP HERE: https://www.ickonic.com/affiliate/josh10 BUY YOUR PRIVATE CLEARPHONE HERE: https://www.r1kln3trk.com/3PC4ZXC/F9D3HK/ LION ENERGY: Never Run Out Of Power! PREPARE NOW! https://www.r1kln3trk.com/3PC4ZXC/D2N14D/ GET VITAMINS AND SUPPLEMENTS FROM DR. ZELENKO HERE: https://zstacklife.com/?ref=WAM GET TIM'S FREE Portfolio Review HERE: https://bit.ly/redpilladvisor And become a client of Tim's at https://www.TheLibertyAdvisor.com STOCK UP ON STOREABLE FOODS HERE: http://wamsurvival.com/ OUR GOGETFUNDING CAMPAIGN: https://gogetfunding.com/help-keep-wam-alive/ OUR PODBEAN CHANNEL: https://worldaltmedia.podbean.com/ Find us on Vigilante TV HERE: https://vigilante.tv/c/world_alternative_media/videos?s=1 FIND US on Rokfin HERE: https://rokfin.com/worldalternativemedia FIND US on Gettr HERE: https://www.gettr.com/user/worldaltmedia See our EPICFUNDME HERE: https://epicfundme.com/251-world-alternative-media JOIN OUR NEWSLETTER HERE: https://www.iambanned.com/ JOIN our Telegram Group HERE: https://t.me/worldalternativemedia JOIN US on Rumble Here: https://rumble.com/c/c-312314 FIND WAM MERCHANDISE HERE: https://teespring.com/stores/world-alternative-media FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media We will soon be doing subscriber only content! Follow us on Twitter here: https://twitter.com/WorldAltMedia Help keep independent media alive! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2024

Last week, we saw some research regarding how a popular tool used to plan breast cancer treatment may be misguiding therapy for Black women, as well as an update on when we can expect to see a new cancer vaccine be readily available for patients.  And on the FDA front, we'll discuss a priority review for Enhertu for patients with HER2-positive solid cancers, as well as a fast track designation for a new drug duo in the lung cancer space.  Cancer Vaccine Likely ‘Several Years' Away From Wide Availability ELI-002 is a vaccine being investigated for the treatment of patients with KRAS-mutant pancreatic or colorectal cancers. While cancer vaccines have been in the headlines a lot in recent months, this one, at least, is still a ways away from being readily available for patients across the United States.  Findings from a phase 1 trial showed that the vaccine could be beneficial for this patient population, and now, a phase 2 trial recently started that will evaluate the efficacy of an injection version of ELI-002, compared to observation. The first patient was dosed in the trial in January 2024, so it could still be several more years until the drug is available, Dr. Christopher Haqq, chief medical officer and vice president, head of research and development at Elicio Therapeutics, said in an interview with CURE®.  “We'll be talking to the regulators like the US Food and Drug Administration and others around the world to align on the data that we'll need to provide for a marketing application. And so, we haven't had that input yet. So I can't give an exact answer for you (on when the vaccine will be commercially available). But we'll work as fast as possible. It's even possible that the type of evidence that we gather in this randomized study could serve that purpose. But we won't know until we have further discussion,” he said.  Test May Be ‘Misguiding' Breast Cancer Treatment for Black Women  A recent study showed that the 21-gene breast recurrence score may lead clinicians away from prescribing chemotherapy to Black women who may benefit from the treatment.  The 21-gene breast recurrence score is the standard test to help guide treatment decisions for patients with estrogen receptor-positive (also known as ER-positive) disease. Most patients with ER-positive cancer undergo hormone therapy, but the outcomes for this test may help decide if a patient would benefit from additional chemotherapy, too. Now, findings from a recent study discovered that Black women — and younger Black women, in particular — may be missing out on chemotherapy that they could potentially benefit from.  Now, this research team is conducting further research looking at potential molecular differences in breast cancer in Black women, as well as how other social disparities could be playing into an increased risk of breast cancer death in these women.  FDA Grants Priority Review to Enhertu for HER2-Positive Solid Cancers  The Food and Drug Administration granted a priority review for a supplemental biologics license to Enhertu for the treatment of patients with previously treated metastatic HER2-positive solid tumors that cannot be removed via surgery. Basically what that means is that the drug showed promise in a clinical trial, and now the FDA will work with the pharmaceutical company developing the drug to expedite the review and potential approval of the agent. The agency plans on making its decision on whether or not Enertu will be approved some time in the second quarter of this year.  Enertu is an antibody drug conjugate, which is a type of drug that works by finding and binding to certain proteins found on cancer cells — in this case, the HER2 protein. The drug was previously approved for patients with lung cancer and metastatic breast cancer, and now, the phase 2 DESTINY-PanTumo02 trial will help determine if it will be approved for patients with endometrial, cervical, ovarian, bladder, biliary tract, pancreatic or other cancers that are HER2 positive.  FDA Grants Fast Track Designation to Avutometinib-Lumakras Combo Also in the regulatory space, the FDA granted a fast track designation to a two drug combination consisting of Lumakras and the novel agent, avutometinib for patients with KRAS G12C-mutant metastatic non-small cell lung cancer. The intended patient population for the regimen is those who have been treated with at least one systemic therapy and have not received a KRAS G12C inhibitor.  The regimen is being investigated in the ongoing phase 1/2 RAMP 203 trial, which will analyze the effectiveness of the drug, as well as the overall response rate — which is the percentage of patients whose cancer decreases from the drug — and safety. Findings from the second phase of the trial, which is specifically looking at patients who have not received or did not respond to a KRAS G12-inhibitor are expected to be published some time in the first half of 2024.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

The FDA is certainly staying busy as 2023 comes to a close, approving three treatments for patients with cancer last week alone. Additionally, exciting study findings were released regarding a cancer vaccine for the treatment of melanoma. FDA Approves Iwilfin for High-Risk Neuroblastoma in Adults and Children The FDA approved has Iwilfin (eflornithine) for the treatment of adult and pediatric patients with high-risk neuroblastoma who have shown at least a partial response to a previous multiagent modality therapy, which includes anti-GD2 immunotherapy. Notably, the FDA reported that this drug is the first approval of a therapy used to reduce the risk of relapse in children with high-risk neuroblastoma. Neuroblastoma, as the National Cancer Institute explained on its website, is a cancer of immature nerve cells that most typically occurs in children, and often begins in the adrenal glands. The FDA said the major efficacy outcome measure behind the approval was event-free survival (EFS; time after treatment when cancer does not come back or worsen; disease progression), while other notable findings included overall survival (OS; length of time from diagnosis or start of treatment when a patient is still alive). FDA Approves Welireg for Advanced Kidney Cancer Subtype The FDA approved Welireg ((beluztifan) for patients with advanced renal cell carcinoma (RCC) who have been previously treated with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). The approval was based on findings from the LITESPARK-005 trial. Trial findings presented earlier this year at the European Society of Medical Oncology Annual Congress (ESMO) showed that at a median follow-up of 18.4 months, patients treated with Welireg experienced objective response rates (patients whose disease responded partially or completely to treatment) of 21.9%, compared with 3.5% among patients treated with Afinitor (everolimus), and 12-month progression-free survival (PFS; the time a patient lives without their disease spreading or worsening) rates were 33.7% on Welireg versus 17.6% with Afinitor, and 18-month PFS rates were 22.5% and 9%, respectively. FDA Approves Padcev-Keytruda Combo in Advanced Bladder Cancer The FDA has additionally approved Padcev (enfortumab vedotin-ejfv) plus Ketruda (pembrolizumab) for patients with locally advanced or metastatic bladder cancer. Alongside this, the FDA previously granted an accelerated approval for this patient population who are unable to be treated with cisplatin-containing chemotherapy. In the recent EV-302/KN-A39 trial, both OS and PFS showed significant improvements among the Padcev plus Keytruda group of patients, as the median overall survival for these patients was 31.5 months, while a cohort treated with chemotherapy experienced a median OS of 16.1 months. Regarding progression-free survival, the median was 12.5 months for the Padcev-Keytruda combination group and 6.3 months in the chemotherapy group. Cancer Vaccine Plus Keytruda Reduces Risk of Recurrence or Death in Melanoma Patients with advanced-stage melanoma continue to experience reduced risk of recurrence or death following treatment with a combination of mRNA vaccine mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), and Keytruda, according to recent study findings. The mRNA-4157 (V940) and Keytruda combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 52% when compared with treatment with Keytruda alone in patients with stage 3 or 4 melanoma with high risk of recurrence following complete resection, as determined by the phase 2b KEYNOTE-942/mRNA-4157-P201 study, according to a news release from drug manufacturers Moderna and Merck. The latest findings, from a median planned follow-up of approximately three years, build on previously announced primarily analysis data from a median planned follow-up of approximately two years which showed that the combination reduced the risk of recurrence or death by 44% and the risk of distance metastasis or death by 65% when compared with Keytruda alone. Based on the trial's findings, the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the combination for the post-surgical treatment of patients with high-risk melanoma earlier this year. Moderna and Merck have also announced the phase 3 INTerpath-001 (V940-001) clinical trial to evaluate the combination as an adjuvant treatment for patients with resected, high-risk stage 3B to 4 melanoma, which is currently enrolling participants, as well as a phase 3 trial for the treatment of patients with non-small cell lung cancer treated with the combination regimen. For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

CNN's Clarissa Ward got rare access to a hospital in southern Gaza where the human toll of the Israel-Hamas war was on display. Lawmakers are set to leave Washington without striking a deal to pass additional funding for Israel and Ukraine. The drugmakers behind an experimental cancer treatment report more progress for people with high-risk forms of melanoma. A woman is suing a Boston fertility doctor for allegedly inseminating her mother with his own sperm secretly. Plus, NASA lost contact with one of the longest-operating spacecrafts in history. Learn more about your ad choices. Visit megaphone.fm/adchoices

On today’s episode, I am speaking with Michelle Cleave. Michelle Cleave was diagnosed with triple…

Dr. Vinod Balachandran explains how he and his colleagues successfully treated pancreatic cancer with bespoke mRNA vaccines. Science journalist Charles Graeber says this could be cancer's “penicillin moment.” This episode was produced by Avishay Artsy, edited by Matt Collette, fact-checked by Laura Bullard, engineered by Michael Raphael, and hosted by Sean Rameswaram. Transcript at vox.com/todayexplained  Support Today, Explained by making a financial contribution to Vox! bit.ly/givepodcasts Learn more about your ad choices. Visit podcastchoices.com/adchoices